|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
ABSTRACT |
|---|
|
|
|---|
Peroxynitrite has been associated with increased oxidative reactions and DNA damage in inflamed tissues as it may cause a reduction of plasma antioxidants as well. Nitration of tyrosine residues of proteins leads to the production of 3-nitrotyrosine (NTYR), which may be considered as a marker of NO·-dependent oxidative damage. We developed a highly sensitive method to detect NTYR in human plasma and tested it in cigarette smokers and in healthy control subjects. Peripheral venous blood (10 ml) was obtained in 20 healthy, asymptomatic cigarette smokers (13 males, 7 females; age: 49 ± 11 yr) and in 18 healthy nonsmokers (10 males and 8 females; age: 36 ± 6 yr). In smokers, plasma nicotine, cotinine, and expired CO levels were measured. NTYR was determined with a sequential HPLC/gas chromatography-thermal energy analysis (GC-TEA) technique. The total plasma Trolox®-equivalent antioxidant capacity (TEAC) was also measured using metmyoglobin as peroxidase and a phenothiazine as a radical donor. NTYR was detectable (detection limit: 0.02 ng/injection) in 11 smokers (mean ± SD: 1.60 ± 1.24 ng/mg protein) and in two nonsmokers (1.10 and 1.20 ng/mg protein, respectively). NTYR was not associated with nicotine and cotinine levels or expired CO in smokers. Plasma TEAC in smokers was significantly lower (0.43 ± 0.38 mM) than in nonsmokers (1.42 ± 0.3 mM; p < 0.001) and showed a biphasic, negative relationship with NTYR (r = 0.96, p < 0.001). This highly sensitive HPLC/GC-TEA method for detection and quantitation of plasma NTYR may be used for monitoring oxidative reactions associated with tobacco smoking. This assay might be incorporated into molecular epidemiologic studies for lung chronic inflammatory and neoplastic disorders in which exposure to oxidants may be an important risk factor.
| |
INTRODUCTION |
|---|
|
|
|---|
Nitric oxide and other free radicals contained in cigarette smoke may trigger oxidation reactions and modify biologic membranes and proteins (1). Through the formation of peroxynitrite after the reaction between nitric oxide and superoxide in inflamed tissues, nitration of tyrosine residues of proteins occurs (2, 3), either on albumin or on lipoproteins (4, 5). Peroxynitrite may also interact with nucleic acids, causing DNA strand breakage (6), and react with guanine residues with the formation of 8-nitroguanine (7), thus contributing to the multistage process of carcinogenesis. Therefore, the formation of nitro-aromatic compounds may represent a useful marker of peroxynitrite-mediated reactions in biologic systems. In this context, the nitration of the ortho position of tyrosine leads to the formation of 3-nitrotyrosine (NTYR), which has been found in animal and human acute lung injury (8, 9) and in serum and synovial fluid of patients with rheumatoid arthritis as a marker of oxidative damage in chronic inflammation (10). Other protein residues, such as phenylalanine and tryptophan, may be nitrated as well by peroxynitrite or nitrogen dioxide (11, 12). NTYR formation after cigarette smoke exposure may thus result either from direct oxidant and free radical activity or from the activation of inflammatory cells in the respiratory tract (13). On the other side, the effects of cigarette smoking on antioxidant defenses are still controversial (14, 15), but it has been shown that the interaction of peroxynitrite with plasma constituents reduces plasma antioxidants (16). We developed a highly sensitive method to detect NTYR in human plasma and tested it in cigarette smokers and in healthy control subjects, along with the measurement of the total plasma antioxidant capacity.
| |
METHODS |
|---|
|
|
|---|
Twenty healthy, asymptomatic cigarette smokers (13 males, 7 females;
mean age: 49 ± 11 yr; average cigarette consumption: 26 ± 8 per day)
and 18 healthy nonsmokers, taken as controls (10 males and 8 females; mean age: 36 ± 6 yr), were studied. FVC, FEV1.0, and FEV1.0/
FVC ratio in smokers were proved to be in the normal range (99.4 ± 14.1%, 99.5 ± 15.2%, and 100.3 ± 8.0% of predicted values, respectively). In smokers, expired CO levels were also determined before
blood sampling. Peripheral venous blood (10 ml) was obtained in each
subject. Plasma samples were prepared soon after blood withdrawal
and stored at
20° C for nicotine and cotinine determination (17) or
immediately processed for measurement of NTYR and total antioxidant capacity.
Measurement of Plasma NTYR
A modified version of the gas chromatography/thermal energy analysis (GC-TEA) method of Ohshima and associates was developed (18). Proteins were extracted from plasma by centrifugation at 500 × g for 15 min, precipitated with ammonium sulfate (80% saturation), and dialyzed (Dialysis Tubing; Medicell International Ltd, London, UK) against distilled water overnight. Dialyzed proteins were then dried under nitrogen, and NTYR was subsequently released by acid hydrolysis in vacuo with 6 N HCl (1 ml) at 110° C for 24 h. Hydrolysates were dried down, resuspended with 1 ml of distilled water, and then applied to C18 end-capped columns (ISOLUTETM; International Sorbent Technology, UK) preconditioned with methanol (6 ml) and 0.05 N HCl (2 ml). Solid-phase extraction of NTYR was performed by applying the sample (1 ml) to the column which was eluted with 7 ml of distilled water. The first 1-ml fraction of the eluate was discarded, and the remaining 6 ml were collected, pooled, and dried down. Fractions and authentic NTYR (2 to 500 ng; Sigma-Aldrich, Milan, Italy) were derivatized with N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide (MTBSFA, 80 µl) and pyridine (20 µl) at 70° C for 20 min. Aliquots (1 µl) of derivatized samples were injected by an automatic sampler into a Hewlett-Packard 5890 gas chromatograph equipped with a Hewlett-Packard capillary column (25 m × 0.32 mm, 0.52-µm film thickness). The injection port was at 295° C, and the column oven was increased from 80° C to 280° C, 70° C/min, by a gradient controller. Helium was used as carrier at a flow rate of 3 ml/min. A thermal energy analyzer (ThermedeTec 543; Analytical Instruments, Woburn, MA) was used as detector with a pyrolyzer temperature of 700° C. Calibration curves were generated with known amounts of NTYR standards, spiked plasma samples, and in vitro nitrosated bovine serum albumin (BSA). To this purpose, formation of NTYR in proteins by nitrating agents was followed by incubating 20 ml of 0.5% BSA with 1.0 mM NaNO2 adjusted to pH 3.5 with acetic acid. The reaction was stopped by adding 5 ml of 25% trichloroacetic acid solution containing 10% (NH4)2SO4. Proteins were precipitated, washed with 10 ml ethanol:ether mixture (1:1), and hydrolyzed as above.
Micropreparative HPLC for Detection of Plasma NTYR
With the above procedure, the presence of a chromatographic peak with authentic NTYR standards could be observed, but the detection of very low amounts of NTYR in human plasma samples was hampered by a high background signal in the neighbor retention times (Figure 1). We therefore decided to add a micropreparative step to the hydrolysates before the injection into the GC-TEA system. Dried hydrolysates were resuspended in distilled water (1 ml) and HPLC separated through a µ-Bondapak C18 column 10 µm, 300 × 3.9 mm; Waters, Milford, MA) fitted with a guard column (4.6 × 45 mm). A quaternary pump (Millipore Co., Waters Division, Milford, MA) coupled with a photodiode array ultraviolet detector was used to control the gradient. Trifluoroacetic acid (1:1,000 vol/vol; BDH, UK) was released 99% for 5 min and then linearly mixed to 90% over 20 min with acetonitrile, which was thereafter increased to 95% over an additional 15 min. The flow rate was 1 ml/min. Given the possibility of nitration of amino acids other than L-tyrosine by nitrating agents, fractions corresponding to L-tyrosine, L-phenylalanine, L-tryptophan, and the corresponding 3-nitro-L-tyrosine, 4-nitro-L-phenylalaine, and 5-nitroindole were identified by ultraviolet spectrophotometry of authentic standards, collected, and dried down for GC-TEA processing.
|
Measurement of Plasma Total Antioxidant Capacity
The total Trolox®-equivalent antioxidant capacity (TEAC) of plasma was measured according to Miller and coworkers (19). Metmyoglobin was obtained by adding myoglobin type III stock solution (400 µM) to an equal volume of freshly prepared 740 µM potassium ferricyanide. The solution was passed through a G15-120 Sephadex column, and the metmyoglobin fraction was collected. Visible spectra were analyzed with a spectrophotometer (Beckman, Fullerton, CA), and absorbance at 490, 560, and 580 nm was measured. After subtracting for background absorbance at 700 nm, the purity of metmyoglobin was estimated by applying the Whitburn equations (20). 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS; 500 µM, 300 µl), metmyoglobin (70 µM, 36 µl), and 497 µl of buffer (of which 4 µl was replaced by plasma in the human experiments) were mixed, and the reaction was initiated by the addition of 167 µl of hydrogen peroxide (450 µM). Visible spectra (450 to 900 nm) were recorded at 90-s intervals for 12 min. The absorbance at 734 nm after 6 min was measured, and the absorbance value of the buffer blank minus the value of the sample divided by the blank value was the fractional inhibition of the reaction. The same procedure was followed with 0.5, 1.0, 1.5, 2.0, and 2.5 mM solutions of Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) in place of plasma, and the inhibition value of plasma was then expressed as Trolox-equivalent from the Trolox dose-inhibition curve (Figure 2).
|
| |
RESULTS |
|---|
|
|
|---|
The normal, non-nitrated, amino acids L-lyrosine, L-phenylalanine, and L-tryptophan can be singled out and identified by HPLC but they did not generate, as expected, GC-TEA signals (data not shown). On the other hand, NTYR and 4-nitro- L-phenylalanine almost coeluted in the HPLC runs with 18 to 19-min retention times, about 15 min earlier than 5-nitroindole (Figure 3, left panels). However, the three nitroamino acids could be singled out by GC-TEA, with the NTYR signal occurring 2 to 3 min later than the other two nitroamino acids (Figure 3, right panels). With this HPLC/GC-TEA technique, NTYR standard was detected down to the limit of 0.02 ng/injection, which represents a 25-fold increase in sensitivity compared with the original method (18). A linear dose-response relationship was observed in the range of 0.02 to 5.00 ng/µl concentration (Figure 4). BSA nitration with different amounts of NaNO2 was linear in the range of 0.037 to 10.540 nmol/mg protein (data not shown).
|
|
NTYR was detectable in plasma of 11 of 20 (55%) healthy cigarette smokers (mean ± SD: 1.60 ± 1.24 ng/mg protein; range: 0.59 to 4.17) and in two of 18 (11%) healthy control subjects (1.10 and 1.20 ng/mg protein, respectively). In smokers, the amount of plasma NTYR was not associated with the number of cigarettes smoked per day or of pack-years, nor was it associated with indicators of active smoking such as blood nicotine (mean: 13.3 ± 6.9 ng/ml; range: 5 to 28) and cotinine (mean: 271.3 ± 101.1 ng/ml; range: 124 to 489) levels and expired CO (mean: 23.0 ± 13.7 ppm; range: 5 to 52) (Table 1). No subjects with GC-TEA peaks at the retention time corresponding to that of authentic 4-nitro-L-phenylalanine were observed in our series. Collecting HPLC fractions at the typical retention time of NTYR (18 to 19 min) prevented the potential noise of GC-TEA tracings with other nitroamino acids, such as 5-nitroindole. A representative GC-TEA chromatogram from a smoker with detectable plasma NTYR is shown in Figure 5.
|
|
Plasma TEAC in smokers was significantly lower (0.43 ± 0.38 mM) than in healthy control subjects (1.42 ± 0.3 mM; p < 0.001), whose value corresponded with the normal reference
value (1.46 ± 0.14 mM) reported from a much greater population sample (19). As shown for NTYR, no relationships between TEAC and the indicators of active and past smoking
were found. Five subjects had extremely low TEAC, corresponding to < 2% inhibition of A734 signal intensity. When
plasma TEAC in smokers was plotted against the corresponding plasma NTYR, a biphasic, negative relationship was observed (r =
0.96, p < 0.001), which was fitted by the expression of TEAC as an exponential function of NTYR (Figure 6).
The two healthy control subjects with detectable plasma
NTYR had TEAC values just around the mean value of that
category group (1.38 and 1.44 mM, respectively).
|
| |
DISCUSSION |
|---|
|
|
|---|
This highly sensitive HPLC/GC-TEA method for detection
and quantitation of plasma NTYR revealed the presence of
this nitroamino acid in 55% of healthy cigarette smokers,
whereas only 11% of control subjects had detectable levels of
NTYR (
2 = 6.27, p = 0.012). This is in contrast with the results
of Ohshima and associates (18), who, on the other hand, sought
to identify and quantitate urinary metabolites of NTYR in humans (actually they measured the major metabolite NHPA).
Interindividual variations in protein metabolism and the contribution of sources of NHPA other than cigarette smoke in
human urine may account for the lack of difference between
smokers and nonsmokers in their study. Direct nitrating agents
in cigarette smoke such as nitric oxide and/or peroxynitrite
formation as a result of cigarette smoke-induced inflammatory
reactions may account for the higher prevalence of NTYR detectability in cigarette smoke-exposed subjects compared with
control subjects (1, 4, 8, 9). None of the study subjects had
known exposure to other pollutants or particular sources of
oxidants. However, other exogenous (e.g., nitrogen dioxide)
and endogenous nitrating agents may have contributed to the
measured level of NTYR in our subjects, in particular in the
healthy nonsmokers (12, 18). Because tyrosine nitration is an
irreversible reaction, NTYR might accumulate into proteins (21)
and thus serve as a stable marker for noninvasive monitoring of cumulative oxidative damage in cigarette smokers, as proposed for circulating F2-isoprostanes and for hydrogen peroxide in the exhaled air (22, 23). The double-step HPLC/GC-TEA
method we used for plasma analysis was specifically focused
on NTYR, although the nitration of other amino acid residues
(such as tryptophan and phenylalanine) in proteins could have
occurred (11, 12). However, none of the samples showed GC-TEA peaks corresponding to 4-nitro-L-phenylalanine, whereas
oxidation of tryptophan to 5-nitroindole, whose detectability
would have been missed in our system, was not observed after
incubation of BSA with 1 mM peroxynitrite (16). In smokers,
no relationships were found between NTYR and estimators of
current and cumulative tobacco smoke exposure (Table 1).
In the same subjects, the presence of oxidative damage was associated with a reduction of the total plasma antioxidant capacity (TEAC), as compared with normal, healthy nonsmokers. The observed level of TEAC in our group of smokers (0.43 ± 0.38 mM) was in the same range of that reported for active and chronic smokers (24) and it corresponded to about one third of TEAC in normal subjects. This confirms that peroxynitrite-mediated reactions may cause depletion of plasma antioxidants (16). For instance, urate, which is estimated to contribute as much as 33% to the total antioxidant activity of plasma (19), has been shown to inhibit tyrosine nitration by peroxynitrite (1, 11). It is seen in Table 1 that three subjects without measurable levels of NTYR had very low TEAC values. This might be due to the direct consumption of antioxidants by tobacco smoke constituents without the priming of peroxynitrite-mediated reactions or to the presence of interfering substances in the assay (such as heme proteins or drugs) which may cause a marked underestimation of TEAC (19). However, in cigarette smokers, oxidative reactions characterized by the formation of NTYR are paralleled by a concomitant consumption of plasma antioxidants that counteract plasma constituent nitration. When we tested for the relationship between plasma NTYR and corresponding TEAC in the 11 smokers with detectable levels of NTYR, a negative, nonlinear relationship was found (Figure 6): for NTYR levels > 0.9 ng/mg protein plasma TEAC was severely reduced (< 0.2 mM in five of six smokers), whereas NTYR levels < 0.9 ng/mg protein were associated with TEAC values in the range of 0.5 to 1.1 mM. This figure is similar to that reported for the relationship between peroxynitrite concentration and thiol content of dialyzed plasma (16). Since thiols in plasma are mainly represented by the cysteine residues of albumin and albumin accounts for ~ 50% of normal TEAC (19), the observed relationship might indicate the reduction of the peroxyl radical-scavenging capacity of plasma proteins while the nitration of tyrosine residues occurs. The nonlinear shape of the above relationship may reflect, at least in part, the requirement for a double oxidation reaction on tyrosine to form NTYR, as reported for nitrogen dioxide (9).
Whatever the route of formation of NTYR might be (auto-oxidation of nitric oxide, peroxynitrite formation), the use of
NTYR as a marker of free radical oxidative damage appears
promising. We herein suggest a highly sensitive, noninvasive
method for NTYR detection and quantitation in plasma, which
seems suitable to monitor oxidation reaction in cigarette
smokers. However, besides being a dosimeter of oxidative
damage, NTYR formation may also have pathophysiologic relevance, since nitration of tyrosine residues on functional proteins such as
1-proteinase inhibitor (25) may directly contribute to the development of emphysema in cigarette smokers.
Therefore, the application of the above techniques in symptomatic smokers and/or patients with chronic obstructive pulmonary disease will be our goal in the near future. However,
in light of the reported genotoxic effect of peroxynitrite (26),
the use of NTYR as a biomarker in molecular epidemiology
studies of human malignancies in which the exposure to nitrosating and alkylating agents is a relevant risk factor may have
even broader applications (27). Its use and that of other biologic markers of exposure to tobacco smoke in easily accessible fluids and cells (28) may represent new tools for preventing tobacco smoke-associated lung diseases.
| |
Footnotes |
|---|
Supported by funds from the CNR Special Project "Applicazioni Cliniche della Ricerca Oncologica" (Contract No. 92.02193.PF39).
Correspondence and requests for reprints should be addressed to Stefano Petruzzelli, M.D., Ph.D., Laboratorio di Biologia Cellulare, U.O. Fisiopatologia Respiratoria, Dipartimento di Cardiologia, Angiologia e Pneumologia, Università di Pisa, via Paradisa 2, 56124 Pisa, Italy.
(Received in original form February 19, 1997 and in revised form July 16, 1997).
Acknowledgments: The writers would like to thank Drs. H. Bartsch (German Cancer Research Center, Heidelberg, Germany) and H. Ohshima (International Agency for Research on Cancer, Lyon, France) for their assistance in the setup of GC-TEA analysis.
| |
References |
|---|
|
|
|---|
1. Eiserich, J. P., V. Vossen, C. A. O'Neill, B. Hallywell, C. E. Cross, and A. van der Vliet. 1994. Molecular mechanisms of damage by excess nitrogen oxides: nitration of tyrosine by gas-phase cigarette smoke. FEBS Lett. 353: 53-56 [Medline].
2. Ischiropoulos, H., and A. B. Al-Mehdi. 1995. Peroxynitrite-mediated oxidative protein modification. FEBS Lett. 364: 279-282 [Medline].
3. Van der Vliet, A., J. P. Eiserich, C. A. O'Neill, B. Hallywell, and C. E. Cross. 1995. Tyrosine modification by reactive oxygen species: a closer look. Arch. Biochem. Biophys. 319: 341-349 [Medline].
4. Gatti, R. M., R. Radi, and O. Augusto. 1994. Peroxynitrite-mediated oxidation of albumin to the protein-thiyl free radical. FEBS Lett. 348: 287-290 [Medline].
5. Beckmann, J. S., Y. Z. Ye, P. G. Anderson, J. Chen, M. A. Accavitti, M. M. Tarpey, and C. R. White. 1994. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol. Chem. Hoppe-Seyler 375: 81-88 [Medline].
6.
Szabo, C.,
B. Zingarelli,
M. O'Connor, and
A. L. Salzman.
1996.
DNA
strand breakage, activation of poly(ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity in macrophages
and smooth muscle cells exposed to peroxynitrite.
Proc. Natl. Acad.
Sci. U.S.A.
93:
1753-1758
7.
Yermilov, V.,
J. Rubio,
M. Becchi,
M. D. Friesen,
B. Pignatelli, and
H. Ohshima.
1995.
Formation of 8-nitroguanine by the reaction of guanine with peroxynitrite in vitro.
Carcinogenesis
16:
2045-2050
8. Haddad, I. Y., G. Pataky, P. Hu, C. Galliani, J. S. Beckman, and S. Matalon. 1994. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J. Clin. Invest. 94: 2407-2413 .
9. Kooy, N. W., J. A. Royall, Y. Z. Ze, D. R. Kelly, and J. S. Beckman. 1995. Evidence for in vivo peroxynitrite production in human lung injury. Am. J. Respir. Crit. Care Med. 151: 1250-1254 [Abstract].
10. Kaur, H., and B. Hallywell. 1994. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation: nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett. 350: 9-12 [Medline].
11. Van der Vliet, A., C. A. O'Neill, B. Hallywell, C. E. Cross, and H. Kaur. 1994. Aromatic hydroxylation and nitration of phenylalanine and tyrosine by peroxynitrite: evidence for hydroxyl radical production from peroxynitrite. FEBS Lett. 339: 89-92 [Medline].
12. Kikugawa, K., T. Kato, and Y. Okamoto. 1994. Damage of amino acids and proteins induced by nitrogen dioxide, a free radical toxin, in air. Free Rad. Biol. Med. 16: 373-382 [Medline].
13.
Haddad, I. Y.,
H. Ischiropoulos,
B. A. Holm,
J. S. Beckman,
J. R. Baker, and
S. Matalon.
1993.
Mechanisms of peroxynitrite-induced injury to
pulmonary surfactant.
Am. J. Physiol.
265:
L555-L564
14. Pacht, E. R., H. Kaseki, J. R. Mohammed, D. G. Cornwell, and W. B. Davis. 1986. Deficiency of vitamin E in the alveolar fluid of cigarette smokers: influence on alveolar macrophage cytotoxicity. J. Clin. Invest. 77: 789-796 .
15. Mezzetti, A., D. Lapenna, S. D. Pierdomenico, A. M. Calafiore, F. Constantini, G. Riario-Sforza, T. Imbastaro, M. Neri, and F. Cuccurullo. 1995. Vitamins E, C and lipid peroxidation in plasma and arterial tissue of smokers and non-smokers. Atherosclerosis 112: 91-99 [Medline].
16. Van der Vliet, A., D. Smith, C. A. O'Neill, H. Kaur, V. Darley-Usmar, C. E. Cross, and B. Hallywell. 1994. Interaction of peroxynitrite with human plasma and its constituent: oxidative damage and antioxidant depletion. Biochem. J. 303: 295-301 .
17. Feyerabend, C., and M. A. H. Russell. 1990. A rapid gas-liquid chromatography method for the determination of cotinine and nicotine in biological fluids. J. Pharm. Pharmacol. 42: 450-452 [Medline].
18. Ohshima, H., M. Friesen, I. Brouet, and H. Barstch. 1990. Nitrotyrosine as a new marker for endogenous nitrosation and nitration of proteins. Food Chem. Toxicol. 28: 647-652 [Medline].
19. Miller, N. J., C. Rice-Evans, M. J. Davies, V. Gopinathan, and A. Milner. 1993. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin. Sci. 84: 407-412 [Medline].
20.
Whitburn, K. D.,
J. J. Shieh,
R. M. Sellers, and
M. Z. Hoffman.
1982.
Redox transformations in ferrimyoglobin induced by radiation-generated free radicals in aqueous solution.
J. Biol. Chem.
257:
1860-1869
21. Salman-Tabcheh, S., M.-C. Guerin, and J. Torreilles. 1995. Nitration of tyrosyl-residues from extra- and intracellular proteins in human whole blood. Free Rad. Biol. Med. 19: 695-698 [Medline].
22.
Morrow, J. D.,
B. Frei,
A. W. Longmire,
J. M. Gaziano,
S. M. Lynch,
Y. Shyr,
W. E. Strauss,
J. A. Oates, and
L. J. Roberts II..
1995.
Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage.
N. Engl. J. Med.
332:
1198-1203
23. Nowak, D., A. Antczak, M. Krol, T. Pietras, B. Shariati, P. Bialasiewicz, K. Jeczkowski, and P. Kula. 1996. Increased content of hydrogen peroxide in the expired breath of cigarette smokers. Eur. Respir. J. 9: 652-657 [Abstract].
24. Rahman, I., D. Morrison, K. Donaldson, and W. MacNee. 1996. Systemic oxidative stress in asthma, COPD, and smokers. Am. J. Respir. Crit. Care Med. 154: 1055-1060 [Abstract].
25. Mierzwa, S., and S. K. Chan. 1987. Chemical modification of human alpha 1-proteinase inhibitor by tetranitromethane: structure-function relationship. Biochem. J. 246: 37-42 [Medline].
26. Yermilov, V., J. Rubio, and H. Ohshima. 1995. Formation of 8-nitroguanidine in DNA treated with peroxynitrite in vitro and its rapid removal from DNA by depurination. FEBS Lett. 376: 207-210 [Medline].
27. Shuker, D. E., V. Prevost, M. D. Friesen, D. Lin, H. Ohshima, and H. Bartsch. 1993. Urinary markers for measuring exposure to endogenous and exogenous alkylating agents and precursors. Environ. Health Perspect. 99: 33-37 [Medline].
28. Petruzzelli, S., L. M. Tavanti, A. Celi, and C. Giuntini. 1996. Detection of N7-methyldeoxyguanosine adducts in human pulmonary alveolar cells. Am. J. Respir. Cell Mol. Biol. 15: 216-223 [Abstract].
This article has been cited by other articles:
![]() |
A. Csiszar, N. Labinskyy, A. Podlutsky, P. M. Kaminski, M. S. Wolin, C. Zhang, P. Mukhopadhyay, P. Pacher, F. Hu, R. de Cabo, et al. Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2721 - H2735. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. An, H. Wang, P. Song, M. Zhang, X. Geng, and M.-H. Zou Nicotine-induced Activation of AMP-activated Protein Kinase Inhibits Fatty Acid Synthase in 3T3L1 Adipocytes: A ROLE FOR OXIDANT STRESS J. Biol. Chem., September 14, 2007; 282(37): 26793 - 26801. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Yanbaeva, M. A. Dentener, E. C. Creutzberg, G. Wesseling, and E. F. M. Wouters Systemic Effects of Smoking Chest, May 1, 2007; 131(5): 1557 - 1566. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Villanueva, C. Cespedes, A. A. Gonzalez, C. P. Vio, and V. Velarde Effect of ischemic acute renal damage on the expression of COX-2 and oxidative stress-related elements in rat kidney Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1364 - F1371. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. H. Hitomi, J. Okuda, H. Nishino, Y. Kambayashi, Y. Hibino, K. Takemoto, T. Takigawa, H. Ohno, N. Taniguchi, and K. Ogino Disposition of Protein-bound 3-nitrotyrosine in Rat Plasma Analysed by a Novel Protocol for HPLC-ECD J. Biochem., April 1, 2007; 141(4): 495 - 502. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yang, A. Zhang, A. Pasumarthy, L. Zhang, Z. Warnock, and J. B. Schnermann Nitric oxide stimulates COX-2 expression in cultured collecting duct cells through MAP kinases and superoxide but not cGMP Am J Physiol Renal Physiol, October 1, 2006; 291(4): F891 - F895. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Rahman and I. M. Adcock Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J., July 1, 2006; 28(1): 219 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. MacNee Treatment of stable COPD: antioxidants Eur. Respir. Rev., September 1, 2005; 14(94): 12 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. MacNee Pulmonary and Systemic Oxidant/Antioxidant Imbalance in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 50 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.W. Boots, G.R.M.M. Haenen, and A. Bast Oxidant metabolism in chronic obstructive pulmonary disease Eur. Respir. J., November 2, 2003; 22(46_suppl): 14s - 27s. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Sugiura, M Ichinose, S Yamagata, A Koarai, K Shirato, and T Hattori Correlation between change in pulmonary function and suppression of reactive nitrogen species production following steroid treatment in COPD Thorax, April 1, 2003; 58(4): 299 - 305. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Pignatelli, C.-Q. Li, P. Boffetta, Q. Chen, W. Ahrens, F. Nyberg, A. Mukeria, I. Bruske-Hohlfeld, C. Fortes, V. Constantinescu, et al. Nitrated and Oxidized Plasma Proteins in Smokers and Lung Cancer Patients Cancer Res., January 1, 2001; 61(2): 778 - 784. [Abstract] [Full Text] |
||||
![]() |
W. MacNee Oxidants/Antioxidants and COPD Chest, May 1, 2000; 117(5_suppl_1): 303S - 317S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Boulos, H. Jiang, and M. Balazy Diffusion of Peroxynitrite into the Human Platelet Inhibits Cyclooxygenase via Nitration of Tyrosine Residues J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 222 - 229. [Abstract] [Full Text] |
||||
![]() |
T. Heitzer, C. Brockhoff, B. Mayer, A. Warnholtz, H. Mollnau, S. Henne, T. Meinertz, and T. Munzel Tetrahydrobiopterin Improves Endothelium-Dependent Vasodilation in Chronic Smokers : Evidence for a Dysfunctional Nitric Oxide Synthase Circ. Res., February 4, 2000; 86 (2): e36 - e41. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Rahman and W. MacNee Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease Am J Physiol Lung Cell Mol Physiol, December 1, 1999; 277(6): L1067 - L1088. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. MACNEE and I. RAHMAN Oxidants and Antioxidants as Therapeutic Targets in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): S58 - 65. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |